Palisade Bio Inc
palisadebio.comWhat Do They Do?
Develops oral drug candidates designed to deliver treatment to the lower intestine for people with inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
10-K for FY2025, filed Mar 20, 2026
How Are They Changing?
Therapy focus
The business shifted from an oral digestive-enzyme inhibitor aimed at preventing surgical adhesions and aiding bowel recovery to oral inhibitor prodrugs for inflammatory bowel diseases.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 20, 2026
Who Do They Compete With?
Competes with AbbVie, Johnson & Johnson, Eli Lilly, Takeda, Pfizer, Bristol Myers Squibb, Merck, Genentech, Teva, Morphic Therapeutic, Ventyx, and Spyre Therapeutics
10-K for FY2025, filed Mar 20, 2026If approved for the treatment of patients with moderate-to-severe IBD, our portfolio of products would compete with TNF antibodies…View ↗
Loading...
